man and woman in lab

Our Science: First, Faster, and for Patients

We’re constantly finding new ways to address patients’ most serious health issues. We concentrate our efforts on a core set of therapeutic areas—ones where we’ve proven our expertise, and where we feel we can have an even greater impact on disease and how it is managed.

Our research & development approach

Science and innovation are the lifeblood of our company. But we’re doing more than developing medicines that perform well in the lab—we’re elevating the current standard of care to bring greater benefits to our patients.

Since our launch in New Zealand, we've invested more than $32.92 million in clinical research. This enables us to discover and deliver innovative medicines and products that solve serious health issues, enhance people's lives today, and address tomorrow's medical challenges


Researching Areas of Unmet Medical Need

At AbbVie, our R&D teams are chasing bold goals. The therapies and solutions that no one else has achieved or even attempted. And we want to be there first. That's what we go after every day for our patients.

A Portfolio of Medicines

We aim to develop innovative therapies for health conditions where there is significant need. Our medicines are approved by Medsafe New Zealand for use in New Zealand.

People

To develop innovative medicines, you need innovative people. Our teams collaborate across disciplines to connect people and ideas, fueling a culture of curiosity and problem-solving.

Pipeline

Our R&D work fuels a dynamic and diverse pipeline that continues to advance and deliver medicines and solutions for patients.

Performance

The need to do more for patients motivates our R&D work. By investing in boundary-pushing approaches, we aim to advance programs with a stronger probability of success and move assets forward faster.

AbbVie’s research pipeline

At a glance: R&D highlights

Our R&D work fuels a dynamic and diverse pipeline that continues to advance and deliver new medicines and solutions for patients. Our scientists are advancing a pipeline of specialty medicines with a focus on cancer, immune-mediated conditions, neurodegenerative diseases and more.

Progress
8
+
active compounds currently being tested in New Zealand
Programs
237
+
patients currently enrolled in clinical trials
impact
40
+
conditions treated across infant, adolescent, adult and senior stages of life in New Zealand.
Investment
$3.6
m
Invested by AbbVie in New Zealand medical research in 2025

Get Involved

Interested in joining our team of innovative scientists and researchers?